Stay updated with breaking news from Hamlet Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical...
/PRNewswire/ -- DelveInsight's Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, bladder cancer...
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1. The new production, at a larger scale, will be essential for future expansions of the clinical trial program in bladder cancer.
Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has secured the production of larger quantities of Alpha1H. The new batch will be essential to extend the clinical trial program in patients with bladder cancer.
The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg. no. 556568-8958, are hereby invited to the extraordinary general meeting on Wednesday, 17 May 2023 at 14:00 at High Court Malmö, Malmöhusvägen 1, SE-211 18 Malmö, Sweden. Registration for the meeting will commence at 13:30.